| 摘要: |
| 目的:观察牛肺表面活性剂联合氨溴索治疗早产儿呼吸窘迫综合征( NRDS) 的临床疗效。方法:选择2012年1月至2014年12月在陕西省人民医院确诊并接受治疗的NRDS早产儿62例,随机分为对照组32例和观察组30例。两组均给予相
同的综合治疗,对照组在综合治疗基础上给予注射用牛肺表面活性剂70~100 mg/kg气管内滴入,观察组给予注射用牛肺表面活性剂(剂量同上)联合静脉滴注氨溴索7.5 mg/ kg治疗,比较两组患儿治疗前后的机械通气参数与血气指标的变化,并比较两组患儿机械通气时间、吸入氧浓度(FiO2)及住院时间。结果:两组治疗前及治疗后血二氧化碳分压(PaCO2)、氧分压(PaO2)、血氧饱和度(SpO2)和pH组内比较差异均有统计学意义(P<0.05);治疗1 h、24 h后两组患儿血PaCO2、PaO2、SpO2和pH比较差异无统计学意义(P>0.05)。治疗后24 h观察组FiO2低于对照组(P<0.05)。两组患儿上机时间及住院时间比较差异无统计学意义(P>0.05)。观察组撤机后氧疗时间较对照组缩短(P<0.05)。结论:牛肺表面活性剂联合氨溴索治疗早产儿RDS可以尽早降低呼吸治疗中吸入氧浓度及撤机后氧疗时间,从而对早产儿的NRDS治疗起到积极作用。 |
| 关键词: 氨溴索 牛肺表面活性剂 新生儿 呼吸窘迫综合征 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2016.08.007 |
|
| 基金项目: |
|
| Clinical Effect of Calf Pulmonary Surfactant Combined with Ambroxol in the Treatment of Premature with Respiratory Distress Syndrome |
| Zhao Zhi, Kang Hua, Lei Hongtao |
| (Shaanxi Province People's Hospital, Shaanxi Xi'an 710068, China) |
| Abstract: |
| Objective: To study the clinical effect of the calf pulmonary surfactant combined with ambroxol in the treatment of premature with neonatal respiratory distress syndrome (NRDS). Methods: Sixty two cases of the NRDS were divided into two groups randomly. The control group (32 cases) was given calf pulmonary surfactant 70-100 mg/ kg dropped into trachea, the observation group (30 cases) on the basis of control group was given intravenous ambroxol 7.5 mg/kg. The mechanical ventilation parameters and arterial blood pH, PaO2 and PaCO2 levels in two groups before and after the treatment were observed. Results: pH, PaO2 , PaCO2 and SpO2 in two groups before and after treatment had significant differences (P>0.05). After 24 hours’ treatment, the FiO2 level was improved in the observation group (P<0.05) and oxygen therapy time was shorter than control group, there were statistically significant differences between two groups (P<0.05). Conclusion: Calf pulmonary surfactant combined with ambroxol in the treatment of premature NRDS can effectively improve FiO2 level in the respiratory therapy and can shorten oxygen therapy time. It is more safe and feasible in the premature. |
| Key words: ambroxol calf pulmonary surfactant neonatal respiratory distress syndrome |
